Literature DB >> 16264436

Acyclic nucleoside phosphonates: a key class of antiviral drugs.

Erik De Clercq1, Antonín Holý.   

Abstract

Almost 20 years after the broad antiviral activity spectrum of the first acyclic nucleoside phosphonates was described, several of these compounds have become important therapies for DNA virus and retrovirus infections. Here, we review the discovery and development of acyclic nucleoside phosphonates, focusing on cidofovir and its potential in the treatment of various herpes-, papilloma-, polyoma-, adeno- and pox-virus infections, adefovir for the treatment of hepatitis B and tenofovir for the treatment of AIDS and the prevention of HIV infections.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16264436     DOI： 10.1038/nrd1877

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  140 in total

Review 1.  Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.

Authors:  Aswani D Vadlapudi; Ramya K Vadlapatla; Ashim K Mitra
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2012-04

2.  Room-temperature alternative to the Arbuzov reaction: the reductive deoxygenation of acyl phosphonates.

Authors:  Sean M A Kedrowski; Dennis A Dougherty
Journal:  Org Lett       Date:  2010-09-17       Impact factor: 6.005

3.  Evaluation of novel acyclic nucleoside phosphonates against human and animal gammaherpesviruses revealed an altered metabolism of cyclic prodrugs upon Epstein-Barr virus reactivation in P3HR-1 cells.

Authors:  Natacha Coen; Sophie Duraffour; Lieve Naesens; Marcela Krecmerová; Joost Van den Oord; Robert Snoeck; Graciela Andrei
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

4.  Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.

Authors:  Andrés Duarte-Rojo; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

5.  Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice.

Authors:  Graciela Andrei; Don B Gammon; Pierre Fiten; Erik De Clercq; Ghislain Opdenakker; Robert Snoeck; David H Evans
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

6.  Molecular Mechanisms for Species Differences in Organic Anion Transporter 1, OAT1: Implications for Renal Drug Toxicity.

Authors:  Ling Zou; Adrian Stecula; Anshul Gupta; Bhagwat Prasad; Huan-Chieh Chien; Sook Wah Yee; Li Wang; Jashvant D Unadkat; Simone H Stahl; Katherine S Fenner; Kathleen M Giacomini
Journal:  Mol Pharmacol       Date:  2018-05-02       Impact factor: 4.436

7.  Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.

Authors:  Minyi Shi; Xin Wang; Erik De Clercq; Sonshin Takao; Masanori Baba
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

Review 8.  The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic.

Authors:  Samuel Broder
Journal:  Antiviral Res       Date:  2009-12-16       Impact factor: 5.970

9.  Acyclic nucleoside bisphosphonates: synthesis and properties of chiral 2-amino-4,6-bis[(phosphonomethoxy)alkoxy]pyrimidines.

Authors:  Petra Doláková; Martin Dracínský; Milena Masojídková; Veronika Solínová; Václav Kasicka; Antonín Holý
Journal:  Eur J Med Chem       Date:  2008-10-02       Impact factor: 6.514

10.  Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides.

Authors:  Mark N Prichard; Debra C Quenelle; Caroll B Hartline; Emma A Harden; Geraldine Jefferson; Samuel L Frederick; Shannon L Daily; Richard J Whitley; Kamal N Tiwari; Joseph A Maddry; John A Secrist; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.